Taliglucerase alfa
Taliglucerase alfa
Taliglucerase alfa (pronunciation: ta-li-gloo-ser-ase al-fa) is a recombinant form of human glucocerebrosidase, an enzyme that is used in the treatment of Gaucher's disease.
Etymology
The name "Taliglucerase alfa" is derived from the words "tali", which is a prefix used in pharmaceutical nomenclature to denote a product's origin, and "glucerase", which refers to the enzyme glucocerebrosidase. The suffix "alfa" is used to denote the first generation of a product.
Usage
Taliglucerase alfa is used as an enzyme replacement therapy (ERT) in patients with Gaucher's disease, a genetic disorder in which a certain type of fat (lipid) accumulates in cells and certain organs. The body needs glucocerebrosidase to break down this fat and prevent it from building up in large amounts.
Mechanism of Action
Taliglucerase alfa works by replacing the deficient glucocerebrosidase enzyme in patients with Gaucher's disease. This helps to reduce the accumulation of the lipid glucocerebroside in the liver, spleen, and bone marrow, thereby alleviating the symptoms of the disease.
Related Terms
- Enzyme replacement therapy (ERT): A medical treatment which replaces an enzyme that is deficient or absent in the body.
- Glucocerebrosidase: An enzyme that breaks down glucocerebrosides, a type of fat that can accumulate in cells and organs in Gaucher's disease.
- Gaucher's disease: A genetic disorder in which a type of fat (lipid) accumulates in cells and certain organs.
External links
- Medical encyclopedia article on Taliglucerase alfa
- Wikipedia's article - Taliglucerase alfa
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski